Pancreatic cancer remains a difficult-to-treat malignancy, yet nab-paclitaxel plus gemcitabine prolongs survival. Closer examination of the mechanism of action of nab-paclitaxel hints at a role for targeting KRAS. We discuss how nab-paclitaxel may be active in pancreatic cancer and how this informs the way forward to better treat patients with pancreatic cancer.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Witkiewicz, A. K. et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat. Commun. 6, 6744 (2015).
Conroy, T. et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N. Engl. J. Med. 364, 1817–1825 (2011).
Von Hoff, D. D. et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N. Engl. J. Med. 369, 1691–1703 (2013).
Von Hoff, D. D. et al. Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial. J. Clin. Oncol. 29, 4548–4554 (2011).
Hidalgo, M. et al. SPARC analysis in the phase III MPACT trial of nab-paclitaxel plus gemcitabine vs gem alone for patients with metastatic pancreatic cancer [abstract]. Ann. Oncol. 25 (Suppl. 2), ii106 (2014). http://annonc.oxfordjournals.org/content/25/suppl_2/ii106.1.full.
Desai, N. et al. Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophorfree, albumin-bound paclitaxel, ABI 007, compared with cremophor-based paclitaxel. Clin. Cancer Res. 12, 1317–1324 (2006).
Thissen, J. A., Gross, J. M., Subramanian, K., Meyer, T. & Casey, P. J. Prenylation-dependent association of Ki-Ras with microtubules. Evidence for a role in subcellular trafficking. J. Biol. Chem. 272, 30362–30370 (1997).
Apolloni, A., Prior, I. A., Lindsay, M., Parton, R. G. & Hancock, J. F. H ras but not K ras traffics to the plasma membrane through the exocytic pathway. Mol. Cell. Biol. 20, 2475–2487 (2000).
Poruchynsky, M. S. et al. Microtubule-targeting agents augment the toxicity of DNA-damaging agents by disrupting intracellular trafficking of DNA repair proteins. Proc. Natl Acad. Sci. USA 112, 1571–1576 (2015).
Bhattacharjee, V., Zhou, Y. & Yen, T. J. A synthetic lethal screen identifies the vitamin D receptor as a novel gemcitabine sensitizer in pancreatic cancer cells. Cell Cycle 13, 3839–3856 (2014).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
PowerPoint slides
Rights and permissions
About this article
Cite this article
Basseville, A., Bates, S. & Fojo, T. Targeting KRAS and the vitamin D receptor via microtubules. Nat Rev Clin Oncol 12, 442–444 (2015). https://doi.org/10.1038/nrclinonc.2015.125
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrclinonc.2015.125